You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
In November 2018, a randomized clinical trial was launched in the midst of an Ebola outbreak in the eastern Democratic Republic of the Congo (DRC). In the trial, conducted at four sites in the country, patients were treated with one of three antibody therapies or an antiviral drug called remdesivir. On 9 August, after reviewing preliminary data on 499 patients, an independent data and safety monitoring board recommended that the trial be stopped. Two of the treatments had shown strong signs of being able to save patients' lives. Now, anyone seeking treatment with Ebola will be offered one of the two drugs, the antibody mAb114 or the antibody cocktail REGN-EB3. Scientists hope this will help bring the outbreak under control, which has grown to be the deadliest in the DRC's history.
